Description
DSIP (Delta Sleep–Inducing Peptide) 5mg – Research Peptide
DSIP (Delta Sleep–Inducing Peptide) 5mg is a high-purity, research-grade peptide supplied for controlled laboratory investigation involving neuropeptide signaling, circadian rhythm biology, and neuroendocrine pathway analysis.
Delta Sleep–Inducing Peptide is referenced in scientific literature as an endogenous peptide associated with neurochemical pathways studied in relation to sleep-stage signaling and circadian rhythm models. Research involving DSIP has examined peptide activity within central nervous system signaling systems and neuroendocrine pathways.
DSIP 5mg is supplied exclusively for in-vitro laboratory research and analytical investigation. This compound is not approved for human or veterinary use.
What Is DSIP?
Delta Sleep–Inducing Peptide (DSIP) is a short-chain peptide identified in early neurochemical research involving sleep-stage signaling.
Scientific literature referencing DSIP has examined its presence in experimental models involving:
• Circadian rhythm signaling pathways
• Neuroendocrine communication systems
• Hormone-related signaling mechanisms during sleep-stage models
• Stress-associated neurochemical pathways
• Central nervous system peptide signaling
These topics represent areas of ongoing experimental investigation within laboratory environments.
Areas of Scientific Investigation
Research literature referencing DSIP has explored experimental models involving:
• Delta-wave sleep signaling pathways
• Circadian rhythm molecular models
• Neuroendocrine pathway analysis
• Hormone signaling interactions within sleep-stage studies
• Central nervous system peptide communication systems
These references are provided for informational context regarding the compound’s presence in scientific research.
Laboratory Research Contexts
Researchers may investigate DSIP within experimental frameworks such as:
• Neuropeptide signaling pathway analysis
• Circadian rhythm laboratory models
• Molecular signaling research involving neuroendocrine systems
• Central nervous system peptide interaction studies
• Peptide structure and stability analysis
DSIP 5mg – Research Supply Specifications
• Synthetic research peptide
• 5mg lyophilized peptide per vial
• Analytical purity standard: 99%+
• Third-party laboratory testing for identity and purity
• Manufactured under controlled quality standards
• Canada-based fulfillment
• Batch-level quality verification
Purity & Quality Assurance
ExoLabz provides research peptides manufactured to high analytical standards. Each batch of DSIP undergoes independent third-party testing to verify peptide identity and purity.
Researchers may perform additional analytical verification if required for laboratory use. If validated testing confirms a verified purity discrepancy, ExoLabz provides refund and testing reimbursement in accordance with company policy.
Important Legal Notice
For Research Purposes Only
DSIP 5mg is supplied strictly for laboratory research and analytical use.
This compound is not intended for human consumption, veterinary use, clinical research involving human subjects, therapeutic use, or diagnostic applications.
This product has not been evaluated or approved by Health Canada, the U.S. Food and Drug Administration (FDA), or any other regulatory authority.
By purchasing this product, the buyer confirms that the material will be handled only by qualified professionals and used solely for lawful laboratory research purposes.
Research Literature
Peer-reviewed studies involving this compound and its class. All findings listed are from in vitro, cell culture or animal models and are provided for scientific reference only. This product is supplied for laboratory research and is not approved for human consumption, clinical, or veterinary use.
- Nakamura A, et al. J Neurochem. 1991;57(3):1013-1018. In rat medullary and regional brain synaptosomes, measured calcium-dependent, tetrodotoxin-insensitive Met-enkephalin release and calcium uptake. Source · PMID 1861139
- Nakamura A, et al. Neuropeptides. 1993;24(3):131-138. In rat brain synaptosome preparations, measured depolarisation-evoked release and aminopeptidase-mediated degradation. Source · PMID 8474631
- Iyer KS, McCann SM Neuroendocrinology. 46(1):93-95. In rat median eminence tissue in vitro, measured dose-dependent inhibition of somatostatin release, blocked by the dopamine antagonist pimozide. Source · PMID 2886936
Literature notes: The publication year for Iyer and McCann is recorded inconsistently across indexes; the identifiers are confirmed.
Related Research Compounds
Browse more compounds in Neuropeptides, or view the full research peptide catalogue.
